182 related articles for article (PubMed ID: 25449777)
21. Overexpression of Fn14 promotes androgen-independent prostate cancer progression through MMP-9 and correlates with poor treatment outcome.
Huang M; Narita S; Tsuchiya N; Ma Z; Numakura K; Obara T; Tsuruta H; Saito M; Inoue T; Horikawa Y; Satoh S; Habuchi T
Carcinogenesis; 2011 Nov; 32(11):1589-96. PubMed ID: 21828059
[TBL] [Abstract][Full Text] [Related]
22. Sterol regulatory element-binding protein 1 is required for ovarian tumor growth.
Nie LY; Lu QT; Li WH; Yang N; Dongol S; Zhang X; Jiang J
Oncol Rep; 2013 Sep; 30(3):1346-54. PubMed ID: 23818099
[TBL] [Abstract][Full Text] [Related]
23. Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo.
Adkins HB; Bianco C; Schiffer SG; Rayhorn P; Zafari M; Cheung AE; Orozco O; Olson D; De Luca A; Chen LL; Miatkowski K; Benjamin C; Normanno N; Williams KP; Jarpe M; LePage D; Salomon D; Sanicola M
J Clin Invest; 2003 Aug; 112(4):575-87. PubMed ID: 12925698
[TBL] [Abstract][Full Text] [Related]
24. Ursolic acid inhibits colorectal cancer angiogenesis through suppression of multiple signaling pathways.
Lin J; Chen Y; Wei L; Hong Z; Sferra TJ; Peng J
Int J Oncol; 2013 Nov; 43(5):1666-74. PubMed ID: 24042330
[TBL] [Abstract][Full Text] [Related]
25. Leukotriene B4 receptor antagonist LY293111 inhibits proliferation and induces apoptosis in human pancreatic cancer cells.
Tong WG; Ding XZ; Hennig R; Witt RC; Standop J; Pour PM; Adrian TE
Clin Cancer Res; 2002 Oct; 8(10):3232-42. PubMed ID: 12374694
[TBL] [Abstract][Full Text] [Related]
26. Tumorigenic role of podoplanin in esophageal squamous-cell carcinoma.
Rahadiani N; Ikeda J; Makino T; Tian T; Qiu Y; Mamat S; Wang Y; Doki Y; Aozasa K; Morii E
Ann Surg Oncol; 2010 May; 17(5):1311-23. PubMed ID: 20066519
[TBL] [Abstract][Full Text] [Related]
27. Enhanced survival in perineural invasion of pancreatic cancer: an in vitro approach.
Dai H; Li R; Wheeler T; Ozen M; Ittmann M; Anderson M; Wang Y; Rowley D; Younes M; Ayala GE
Hum Pathol; 2007 Feb; 38(2):299-307. PubMed ID: 17097719
[TBL] [Abstract][Full Text] [Related]
28. Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy.
Kioi M; Kawakami M; Shimamura T; Husain SR; Puri RK
Cancer; 2006 Sep; 107(6):1407-18. PubMed ID: 16902988
[TBL] [Abstract][Full Text] [Related]
29. Qingyihuaji formula inhibits progress of liver metastases from advanced pancreatic cancer xenograft by targeting to decrease expression of Cyr61 and VEGF.
Yin JH; Shi WD; Zhu XY; Chen Z; Liu LM
Integr Cancer Ther; 2012 Mar; 11(1):37-47. PubMed ID: 21382954
[TBL] [Abstract][Full Text] [Related]
30. Promoted cancer growth by stimulating cell proliferation and decreasing apoptosis using a lentivirus-based EphB2 RNAi in pancreatic carcinoma CFPAC-1 cells.
Hua YQ; Ouyang HQ; Chen Z; Meng ZQ; Luo JM; Lin JH; Zhou ZH; Chen H; Wang K; Liu LM
Biomed Pharmacother; 2011 Mar; 65(2):123-31. PubMed ID: 21292437
[TBL] [Abstract][Full Text] [Related]
31. Activation of AKT signaling promotes epithelial-mesenchymal transition and tumor growth in colorectal cancer cells.
Suman S; Kurisetty V; Das TP; Vadodkar A; Ramos G; Lakshmanaswamy R; Damodaran C
Mol Carcinog; 2014 Feb; 53 Suppl 1():E151-60. PubMed ID: 24000138
[TBL] [Abstract][Full Text] [Related]
32. Visceral adipose tissue remodeling in pancreatic ductal adenocarcinoma cachexia: the role of activin A signaling.
Xu PC; You M; Yu SY; Luan Y; Eldani M; Caffrey TC; Grandgenett PM; O'Connell KA; Shukla SK; Kattamuri C; Hollingsworth MA; Singh PK; Thompson TB; Chung S; Kim SY
Sci Rep; 2022 Jan; 12(1):1659. PubMed ID: 35102236
[TBL] [Abstract][Full Text] [Related]
33. miR-145, targeting high-mobility group A2, is a powerful predictor of patient outcome in ovarian carcinoma.
Kim TH; Song JY; Park H; Jeong JY; Kwon AY; Heo JH; Kang H; Kim G; An HJ
Cancer Lett; 2015 Jan; 356(2 Pt B):937-45. PubMed ID: 25444913
[TBL] [Abstract][Full Text] [Related]
34. Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy.
Lonardo E; Hermann PC; Mueller MT; Huber S; Balic A; Miranda-Lorenzo I; Zagorac S; Alcala S; Rodriguez-Arabaolaza I; Ramirez JC; Torres-Ruíz R; Garcia E; Hidalgo M; Cebrián DÁ; Heuchel R; Löhr M; Berger F; Bartenstein P; Aicher A; Heeschen C
Cell Stem Cell; 2011 Nov; 9(5):433-46. PubMed ID: 22056140
[TBL] [Abstract][Full Text] [Related]
35. Total alkaloids of Rubus aleaefolius Poir. inhibit the STAT3 signaling pathway leading to suppression of proliferation and cell cycle arrest in a mouse model of hepatocellular carcinoma.
Zhao J; Lin W; Cao Z; Liu L; Zhuang Q; Zhong X; Hong Z; Peng J
Oncol Rep; 2013 Sep; 30(3):1309-14. PubMed ID: 23828071
[TBL] [Abstract][Full Text] [Related]
36. Silibinin-mediated metabolic reprogramming attenuates pancreatic cancer-induced cachexia and tumor growth.
Shukla SK; Dasgupta A; Mehla K; Gunda V; Vernucci E; Souchek J; Goode G; King R; Mishra A; Rai I; Nagarajan S; Chaika NV; Yu F; Singh PK
Oncotarget; 2015 Dec; 6(38):41146-61. PubMed ID: 26510913
[TBL] [Abstract][Full Text] [Related]
37. Sex specificity of pancreatic cancer cachexia phenotypes, mechanisms, and treatment in mice and humans: role of Activin.
Zhong X; Narasimhan A; Silverman LM; Young AR; Shahda S; Liu S; Wan J; Liu Y; Koniaris LG; Zimmers TA
J Cachexia Sarcopenia Muscle; 2022 Aug; 13(4):2146-2161. PubMed ID: 35510530
[TBL] [Abstract][Full Text] [Related]
38. Paracrine Activin-A Signaling Promotes Melanoma Growth and Metastasis through Immune Evasion.
Donovan P; Dubey OA; Kallioinen S; Rogers KW; Muehlethaler K; Müller P; Rimoldi D; Constam DB
J Invest Dermatol; 2017 Dec; 137(12):2578-2587. PubMed ID: 28844941
[TBL] [Abstract][Full Text] [Related]
39. Combined treatment of carfilzomib and z-VAD-fmk inhibits skeletal proteolysis and apoptosis and ameliorates cancer cachexia.
Wang Q; Li C; Peng X; Kang Q; Deng D; Zhang L; Zheng Y; Wang C; Qiao Z; Guo D; You S; Tang H
Med Oncol; 2015 Apr; 32(4):100. PubMed ID: 25737433
[TBL] [Abstract][Full Text] [Related]
40. Homozygous deletion of the activin A receptor, type IB gene is associated with an aggressive cancer phenotype in pancreatic cancer.
Togashi Y; Sakamoto H; Hayashi H; Terashima M; de Velasco MA; Fujita Y; Kodera Y; Sakai K; Tomida S; Kitano M; Ito A; Kudo M; Nishio K
Mol Cancer; 2014 May; 13():126. PubMed ID: 24886203
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
